Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases

Key Takeaways

• Argo Biopharma has dosed the first patients in Phase II clinical trials of BW-40202, an siRNA therapy targeting complement factor B
• The investigational treatment is being evaluated for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN), both rare diseases with limited treatment options
• Phase II trials represent a significant advancement from earlier studies, bringing the potential therapy closer to market availability for patients

---

Argo Biopharma Advances siRNA Therapy Development

Argo Biopharmaceutical Co., Ltd., a clinical-stage small interfering RNA (siRNA) therapeutics company, announced on April 20, 2026, that it has dosed the first patients in multiple Phase II clinical trials of BW-40202. The investigational siRNA therapy targets complement factor B (CFB) and is being evaluated for two distinct rare disease indications.

Targeting Rare Complement-Mediated Diseases

BW-40202 is being studied in separate Phase II trials for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN). Both conditions are rare diseases characterized by complement system dysregulation, making them potential targets for complement factor B inhibition.

PNH is a rare acquired blood disorder that affects red blood cells, while IgAN is the most common form of glomerulonephritis worldwide, though still considered rare in many regions. Current treatment options for both conditions remain limited, creating significant unmet medical need.

siRNA Technology Approach

The siRNA therapeutic approach used by Argo Biopharma represents an innovative method for targeting complement factor B. By using small interfering RNA molecules, BW-40202 aims to reduce the production of complement factor B protein, potentially offering a more targeted approach than traditional complement inhibitors.

Clinical Development Milestone

The initiation of Phase II trials marks a crucial advancement in BW-40202’s development timeline. These studies will provide important efficacy and safety data that could support future regulatory submissions. The dual-indication approach allows Argo Biopharma to maximize the therapeutic potential of their complement factor B targeting strategy.

Market Implications

The rare disease therapeutics market continues to attract significant investment, particularly for innovative approaches like siRNA therapy. Success in these Phase II trials could position Argo Biopharma as a key player in the complement inhibition space, competing with established therapies while potentially offering improved dosing convenience or efficacy profiles.

---

Frequently Asked Questions

What conditions is BW-40202 being tested for?

BW-40202 is being evaluated in separate Phase II clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN), both rare diseases involving complement system dysfunction.

When will BW-40202 be available to patients?

BW-40202 is currently in Phase II trials, meaning it’s still several years away from potential market availability. If successful, Phase III trials and regulatory review would still be required before approval.

How does siRNA therapy work differently from existing treatments?

siRNA therapy works by reducing the production of specific proteins at the genetic level, potentially offering more targeted and sustained effects compared to traditional drugs that block proteins after they’re already made.